Commitments and Contingencies - Additional Information (Detail)	3 Months Ended		6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Mar. 31, 2015 USD ($)	Jun. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) € / $ shares	Sep. 30, 2016 EUR (€) shares	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 29, 2015 USD ($)
Commitments And Contingencies [Line Items]
Agreed to pay the customer and settlement of claim									$ 2,500,000
Undisputed royalties earned									$ 500,000
Revenue recognized by company	$ 500,000
Pre tax compensation expense	$ 2,500,000
Additional shares of common stock to stockholders | shares					480,059	480,059
License agreement commencement date					2006-03	2006-03
Annual minimum payments for licenses					$ 224,000	€ 200,000
Exchange rate relating to license payment | € / $					1.1222
Future minimum payments associated with license					$ 2,700,000
Additional maximum amount payable on successful achievement of specified milestones to sellers of PR Pharma					$ 2,500,000
Indemnification period					5 years	5 years
Indemnification period expired date					Nov. 17, 2016	Nov. 17, 2016
Additional indemnification claims					$ 0
Rent expense related to operating leases					$ 100,000		$ 100,000	$ 100,000
Maximum [Member]
Commitments And Contingencies [Line Items]
Rights to receive contingent consideration		$ 100,000
Patents [Member]
Commitments And Contingencies [Line Items]
Patent expiry date					2027-09	2027-09
January 2009 through September 2014 [Member]
Commitments And Contingencies [Line Items]
Royalties overpaid			$ 5,700,000	$ 5,700,000